At 4TEEN4 we are researching diseases related to circulating dipeptidyl peptidase 3 (DPP3), a biomarker and target for our therapeutic antibody Procizumab.
Location: Germany
Total raised: $72.76M
Investors 1
| Date | Name | Website |
| - | BFB Brande... | brandenbur... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.11.2025 | Series C | $64.32M | - |
| - | Series A | $8.43M | - |
Mentions in press and media 11
| Date | Title | Description |
| 30.07.2026 | Brandenburg Kapital - News about 4TEEN4 Pharmaceuticals GmbH | Potsdam, Hennigsdorf - July 2026 - The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Brandenburg Kapital's portfolio company 4TEEN4 Pharmaceuticals GmbH (4TEEN4) for its drug candidate for the treatment of ca... |
| 04.05.2026 | Brandenburg Kapital - Looking back on 2025 | 2025 impressively confirmed how much growth power there is in our portfolio - and how much potential still lies ahead of us. In total, Brandenburg Kapital GmbH invested around €17 million in new and follow-up investments in 2025. Thanks go ... |
| 04.05.2026 | Brandenburg Kapital - News about 4TEEN4 Pharmaceuticals GmbH | Potsdam, November 2025 - 4TEEN4 Pharmaceuticals has successfully extended its Series C financing round, securing a total of €55 million to advance the development of its next-generation shock therapy procizumab. The round was supported by s... |
| 18.11.2025 | 4TEEN4 Pharma Secures €55M for Cardiogenic Shock Drug | 4TEEN4 Pharmaceuticals got €55M. The money will boost their drug for cardiogenic shock. Procizumab is the drug. It targets a key cause of this deadly condition. Trials are expanding in Europe. US trials are planned. This investment fuels ho... |
| 16.11.2025 | 4TEEN4 Pharmaceuticals Extends Series C To €55 Million To Advance Clinical Development Of Procizumab In Cardiogenic Shock | 4TEEN4 Pharmaceuticals has expanded its Series C financing round to €55 million, securing participation from both existing and new investors to accelerate the development of its lead monoclonal antibody therapy, procizumab, for patients suf... |
| 13.11.2025 | 4TEEN4 Extends Series C Financing Round to €55M | 4TEEN4, a Berlin, Germany-based pharmaceutical company which specializes in critical care management, raised €55M in Series C extension funding. Backers included existing and new investors. Led by CEO Dr. Andreas Bergmann, 4TEEN4 is develop... |
| 11.04.2022 | Dipeptidyl Peptidase 3 Biomarker to Drive Precision Medicine in COVID-19 | Dipeptidyl Peptidase 3 release is a fatal clinical pathway in severe COVID-19 patients resulting in organ dysfunction and short-term mortality New COVID-19 trial conducted by University Hospital Hamburg-Eppendorf is implementing a biomarker... |
| 01.12.2021 | 4TEEN4 Pharmaceuticals Selects AGC Biologics to Manufacture Procizumab | AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) to manufacture and commercialize Procizumab. The fir... |
| 25.03.2021 | 4TEEN4 Pharmaceuticals GmbH: DPP3 predicts organ failure and in-hospital mortality in post-operative patients | DGAP-News: 4TEEN4 Pharmaceuticals GmbH / Key word(s): Study/Study results 4TEEN4 Pharmaceuticals GmbH: DPP3 predicts organ failure and in-hospital mortality in post-operative patients 25.03.2021 / 10:00 The issuer is solely responsible for ... |
| - | Biotech Startup 4TEEN4 Pharmaceuticals Closes EUR 7 Million Series A Financing | Hennigsdorf/Berlin, Germany, December, 2019 – 4TEEN4 Pharmaceuticals GmbH (formerly Sphingotec Therapeutics GmbH) announced today the closing of a EUR 6.9 million Series A financing round. The new funds will be used to advance the preclinic... |
Show more